Antibody complementarity-determining regions (cdrs): A bridge between adaptive and innate immunity

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Gabrielli, Elena ^a   Pericolini, Eva ^a   Cenci, Elio ^a   Ortelli, Federica ^a   Magliani, Walter ^b   Ciociola, Tecla ^b   Bistoni, Francesco ^a   Conti, Stefania ^b   Vecchiarelli, Anna ^a   Polonelli, Luciano ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTIFUNGAL AGENT; IMMUNOGLOBULIN HEAVY CHAIN; PEPTIDE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CANDIDIASIS; CELL POPULATION; CELL SURVIVAL; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; SPLEEN CELL; UPREGULATION; ANIMAL; BIOSYNTHESIS; CANDIDA ALBICANS; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; NEUTROPHIL; PATHOLOGY; PERITONEUM MACROPHAGE; SURVIVAL;

ADAPTIVE IMMUNITY; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COMPLEMENTARITY DETERMINING REGIONS; ENZYME ACTIVATION; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOMODULATION; MACROPHAGES, PERITONEAL; MICE; NEUTROPHILS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77949518721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008187     Document Type: Article

References (43)

1. Alzari PM, Lascombe MB, Poljak RJ (1988) Three-dimensional structure of antibodies. Annu Rev Immunol 6: 555-580.
2. Davies DR, Padlan EA, Sheriff S (1990) Antibody-antigen complexes. Annu Rev Biochem 59: 439-473.
3. Padlan EA (1994) Anatomy of the antibody molecule. Mol Immunol 31: 169-217.
4. Shirai H, Kidera A, Nakamura H (1996) Structural classification of CDR-H3 in antibodies. FEBS Lett 399: 1-8.
5. Davies DR, Cohen GH (1996) Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A 93: 7-12.
6. Padlan EA, Abergel C, Tipper JP (1995) Identification of specificity-determining residues in antibodies. Faseb J 9: 133-139.
7. Eisenhardt SU, Schwarz M, Schallner N, Soosairajah J, Bassler N, et al. (2007) Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents. Blood 109: 3521-3528.
8. Polonelli L, Magliani W, Conti S, Bracci L, Lozzi L, et al. (2003) Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 71: 6205-6212.
9. Cenci E, Bistoni F, Mencacci A, Perito S, Magliani W, et al. (2004) A synthetic peptide as a novel anticryptococcal agent. Cell Microbiol 6: 953-961.
10. Travassos LR, Silva LS, Rodrigues EG, Conti S, Salati A, et al. (2004) Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J Antimicrob Chemother 54: 956-958.
11. Manfredi M, McCullough MJ, Conti S, Polonelli L, Vescovi P, et al. (2005) In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiol Immunol 20: 226-232.
12. Fiori PL, Mattana A, Dessi D, Conti S, Magliani W, et al. (2006) In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. J Antimicrob Chemother 57: 891-898.
13. Savoia D, Scutera S, Raimondo S, Conti S, Magliani W, et al. (2006) Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes. Exp Parasitol 113: 186-192.
14. Casoli C, Pilotti E, Perno CF, Balestra E, Polverini E, et al. (2006) A killer mimotope with therapeutic activity against AIDS-related opportunistic microorganisms inhibits ex-vivo HIV-1 replication. Aids 20: 975-980.
15. Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, et al. (2008) Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection. Antimicrob Agents Chemother 52: 4331-4337.
16. Cenci E, Pericolini E, Mencacci A, Conti S, Magliani W, et al. (2006) Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J Leukoc Biol 79: 40-45.
17. Pertinhez TA, Conti S, Ferrari E, Magliani W, Spisni A, et al. (2009) Reversible self-assembly: a key feature for a new class of autodelivering therapeutic peptides. Mol Pharm 6: 1036-1039.
18. Sevilla MJ, Robledo B, Rementeria A, Moragues MD, Ponton J (2006) A fungicidal monoclonal antibody protects against murine invasive candidiasis. Infect Immun 74: 3042-3045.
19. Moragues MD, Omaetxebarria MJ, Elguezabal N, Sevilla MJ, Conti S, et al. (2003) A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect Immun 71: 5273-5279.
20. Tuteja R (1999) B-cell responses to a peptide epitope: mutations in heavy chain alone lead to maturation of antibody responses. Immunology 97: 1-8.
21. Nickerson KG, Tao MH, Chen HT, Larrick J, Kabat EA (1995) Human and mouse monoclonal antibodies to blood group A substance, which are nearly identical immunochemically, use radically different primary sequences. J Biol Chem 270: 12457-12465.
22. Polonelli L, Ponton J, Elguezabal N, Moragues MD, Casoli C, et al. (2008) Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS ONE 3: e2371
23. De Smet K, Contreras R (2005) Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27: 1337-1347.
24. Mookherjee N, Hancock RE (2007) Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 64: 922-933.
25. Chen HT, Kabat EA, Lundblad A, Ratcliffe RM (1987) Nucleotide and translated amino acid sequences of cDNA coding for the variable regions of the light and heavy chains of mouse hybridoma antibodies to blood group A and B substances. J Biol Chem 262: 13579-13583.
26. Azuma M (2006) Fundamental mechanisms of host immune responses to infection. J Periodontal Res 41: 361-373.
27. Dillon RL, White DE, Muller WJ (2007) The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26: 1338-1345.
28. Hawkins PT, Anderson KE, Davidson K, Stephens LR (2006) Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 34: 647-662.
29. Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13: 816-825.
30. Allen MP, Zeng C, Schneider K, Xiong X, Meintzer MK, et al. (1999) Growth arrest-specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signalregulated kinase (ERK) and Akt. Mol Endocrinol 13: 191-201.
31. Liew FY, Xu D, Brint EK, O'Neill LA (2005) Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5: 446-458.
32. Nhu QM, Cuesta N, Vogel SN (2006) Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2). J Endotoxin Res 12: 285-295.
33. Fan H, Williams DL, Zingarelli B, Breuel KF, Teti G, et al. (2007) Differential regulation of lipopolysaccharide and Gram-positive bacteria induced cytokine and chemokine production in macrophages by Galpha(i) proteins. Immunology 122: 116-123.
34. Armstrong L, Medford AR, Hunter KJ, Uppington KM, Millar AB (2004) Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 136: 312-319.
35. Levi M, Sallberg M, Ruden U, Herlyn D, Maruyama H, et al. (1993) A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 90: 4374-4378.
36. Bourgeois C, Bour JB, Aho LS, Pothier P (1998) Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Virol 72: 807-810.
37. Shealy DJ, Visvanathan S (2008) Anti-TNF antibodies: lessons from the past, roadmap for the future. Handb Exp Pharmacol. pp 101-129.
38. Naito M (2008) Macrophage differentiation and function in health and disease. Pathol Int 58: 143-155.
39. Monari C, Pericolini E, Bistoni G, Casadevall A, Kozel TR, et al. (2005) Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages. J Immunol 174: 3461-3468.
40. Kawai T, Akira S (2005) Pathogen recognition with Toll-like receptors. Curr Opin Immunol 17: 338-344.
41. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, et al. (2002) The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 185: 1483-1489.
42. Litman GW, Cannon JP, Dishaw LJ (2005) Reconstructing immune phylogeny: new perspectives. Nat Rev Immunol 5: 866-879.
43. Romani L, Mencacci A, Cenci E, Spaccapelo R, Mosci P, et al. (1993) CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J Immunol 150: 925-931.